Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR113244 in Systemic Lupus Erythematosus
NCT02321709Phase 1Completed
- Sponsor
- Sanofi
- Start
- Nov 2014
- Primary completion
- Mar 2016
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of SAR113244 in systemic lupus erythematosus (SLE) (3 cohorts), sponsored by Sanofi. Primary endpoints: Number of participants with adverse events and treatment-emergent adverse events at 16 weeks, Change in physical examination, body weight, vital signs and laboratory parameters at 16 weeks and 1 more. Started Nov 2014; status: completed.
02
Drugs
SAR113244
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT02321709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02321709.